Tagreed Alkaltham: Tranexamic Acid in PBM
Tagreed Alkaltham, Transfusion Medicine Lab Supervisor at KSMC, shared a post on LinkedIn:
“Tranexamic Acid (TXA) in PBM
Not a bleeding drug. A timing decision.
Tranexamic acid is often described as a medication for bleeding. But in Patient Blood Management, TXA is something else entirely. It is a decision about timing.
Bleeding doesn’t usually start out of control. It becomes uncontrolled when early structure is missed.
TXA works best in that narrow window when clot integrity is still protectable, and before bleeding escalates into loss of control.
Used early, TXA protects the newly forming clot from premature breakdown. Used late, it can only limit further damage.
From a PBM perspective, TXA is not about stopping blood loss after it happens. It’s about preventing escalation.
When given at the right time, TXA:
- preserves clot integrity
- reduces escalation
- lowers transfusion needs
Not because it replaces blood but because it protects the system from needing more of it.
From a Blood Bank Perspective:
TXA is not seen as a bleeding medication. It is seen as an early stabilizing decision.
When TXA is administered early, it often prevents the rapid cascade that follows uncontrolled bleeding: massive transfusion activation, sudden inventory pressure, and reactive decisions made under urgency rather than design.
Early TXA preserves more than clot integrity. It preserves options.
It allows the blood bank to respond within a controlled, balanced framework, instead of being pulled abruptly into crisis mode.
When TXA is delayed, the blood bank is rarely responding to bleeding alone, it is responding to escalation, narrowed choices, and loss of control.
PBM doesn’t fail when bleeding occurs. It fails when early decisions are delayed.
And TXA reminds us of a simple truth:
Timing is the intervention before blood is needed.”
Find more posts featuring Tagreed Alkaltham on Hemostasis Today.
-
Jul 14, 2026, 19:35Daratumumab in Difficult-to-Treat iTTP: Updated Results from the International DarTTP Study
-
Jul 14, 2026, 17:1610 Posts Not To Miss from ISTH 2026, Part 3
-
Jul 14, 2026, 15:27Dianne E Van Der Wal: Celebrating Scientific Contributions at ISTH 2026
-
Jul 14, 2026, 15:13Alfonso Tafur: RIETE Registry Analysis Supports More Equitable Approaches to VTE Care
-
Jul 14, 2026, 15:03Heghine Khachatryan: Phase III Trial Results Support BAFF-R Inhibition in Corticosteroid-Refractory ITP
-
Jul 14, 2026, 14:51Nathan Connell: ISTH 2026 Highlights the Power of Lifelong Collaboration
-
Jul 14, 2026, 14:42Wolfgang Miesbach: VOYAGER1 Highlights Progress Toward Injection-Free Care in Hemophilia A
-
Jul 14, 2026, 12:08Elvira Grandone: Finding the Right LMWH Dose for Pregnant Patients Suffering From DVT
-
Jul 14, 2026, 12:05Eloïse Laouenan: From Washington to Paris – Join GETBO at ISTH 2026